MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

Press/Media: Public EngagementPopular

Description

NEW YORK,Nov. 16, 2021/PRNewswire/ -- Mind Medicine (MindMed) Inc. ... Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response. The study will be conducted by Dr. Kim Kuypers of Maastricht University, a leading global authority on the use of low dose psychedelics. ...

Period16 Nov 2021

Media coverage

2

Media coverage

  • TitleMindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
    Degree of recognitionInternational
    Media name/outletTicker Technologies
    Media typeOnline
    Country/TerritoryUnited States
    Date16/11/21
    DescriptionNEW YORK, Nov. 16, 2021/PRNewswire/ -- Mind Medicine (MindMed) Inc. ... Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response. The study will be conducted by Dr. Kim Kuypers of Maastricht University, a leading global authority on the use of low dose psychedelics. ...
    Producer/AuthorPR Newswire
    URLwww.tickertech.com/cgi/?a=news&ticker=a&w=&story=202111202111160730PR_NEWS_USPR_____LA76089
    PersonsKim Kuypers
  • TitleMindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
    Degree of recognitionInternational
    Media name/outletTicker Technologies
    Media typeOnline
    Country/TerritoryUnited States
    Date16/11/21
    DescriptionNEW YORK,Nov. 16, 2021/PRNewswire/ -- Mind Medicine (MindMed) Inc. ... Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response. The study will be conducted by Dr. Kim Kuypers of Maastricht University, a leading global authority on the use of low dose psychedelics. ...
    Producer/AuthorTickertech.com
    URLwww.tickertech.com/cgi/?a=news&ticker=a&w=&story=202111202111160730CANADANWCANADAPR_C5366
    PersonsKim Kuypers

Keywords

  • LSD on neuroplasticity
  • MindMed executive team
  • MindMed trades
  • actual results
  • applicable securities laws
  • benefits
  • clinical trial risks
  • compelling drug development pipeline
  • compliance with laws
  • digital medicine measurement techniques